奥拉西坦治疗血管性认知功能障碍的效果及安全性评价

Effect and safety of oxiracetam in treating vascular cognitive impairment

目的 评价奥拉西坦治疗血管性认知功能障碍（VCI）的效果及安全性.方法 选取2012年2月至2013年8月武汉市中心医院神经内科收治的88例VCI患者.完全随机分为观察组和对照组,各44例.对照组给予常规治疗,观察组在对照组基础上服用奥拉西坦胶囊,800 mg/次,3次/d,疗程均为12周,通过简易精神状态量表（MMSE）、临床痴呆评定量表（CDR）、巴氏指数、美国国立卫生研究院卒中量表（NIHSS）进行评分,评价2组疗效,并记录治疗期间的不良反应.结果 治疗前2组MMSE、CDR、巴氏指数、NIHSS评分差异均无统计学意义（均P＞0.05）.治疗后2组与本组治疗前差异有统计学意义（P＜0.05）;且治疗后观察组MMSE评分、巴氏指数高于对照组,CDR、NIHSS评分评分低于对照组,差异均有统计学意义[（23±5）分比（20±3）分、（76±5）分比（71±6）分、（1.36±0.26）分比（1.62±0.29）分、（16±5）分比（19±5）分,均P ＜0.05].除观察组2例出现轻微胃肠道反应外,余患者均未见其他不良反应.结论 奥拉西坦治疗血管性认知功能障碍疗效确切,且安全性高.

Objective To evaluate the curative effect and safety of oxiracetam in treating vascular cognitive impairment （VCI）.Methods Totally 88 VCI patients from February 2012 to August 2013 were randomly divided into control group （44 cases） and observation group （44 cases）.Control group was given routine treatment and observation group was administered with oxiracetam （800 mg/time,3 times/d,oral） on the basis of routine treatment;the treatment lasted for 12 weeks.The mini mental state examination （MMSE）,Clinical Dementia Rating （CDR）,barthel index （BI） and national institute of health stroke scale （NIHSS） were used to assess the curative effect;the adverse reactions during treatment were recorded.Results The scores of MMSE,CDR,BI and NIHSS before treatment were not significantly different between groups （P 〉 0.05）.After treatment,all the scores were improved in both groups （P 〈 0.05）,in addition,the scores of MMSE,BI were significantly higher than,the scores of CDR and NIHSS were significantly lower than in observation group that those in control group [（23 ± 5） scores vs （20 ± 3） scores,（76 ± 5） scores vs （71 ± 6） scores,（1.36 ± 0.26） scoresvs （1.62 ±0.29） scores,（16 ±5） scores vs （19 ±5） scores] （P〈0.05）.Two cases in observation group had mild gastrointestinal reactions,all the other patients showed no adverse reactions.Conclusion Oxiracetam has good curative effect in treating vascular cognitive impairment,and the safety is good.